Dear Members,
The Board of Directors ("the Board") of the Company is pleased to present the
20th Annual Report of Innova Captab Limited ("the Company" or
"ICL') along with the Audited (Standalone and Consolidated) Financial Statements for
the Financial Year ("FY") ended 31 March 2024 (hereinafter referred as "FY
2024" or "during the year"). This is the first annual report after the
Initial Public Offering ("IPO") of the Company. The Board appreciates and is
thankful for the continued support of all the shareholders throughout the journey of the
Company from incorporated as private limited company, conversion into public limited
company and now as a listed company.
1. FINANCIAL PERFORMANCE
The audited financial statements of the Company for FY 2024 are prepared in accordance
with the relevant applicable Indian Accounting Standards ('Ind AS') and Regulation 33 of
the Securities and Exchange Board of India (Listing Obligations and Disclosure
Requirements) Regulations, 2015 ("SEBI Listing Regulations") and the provisions
of the Companies Act, 2013 ("Act").
The table below sets forth the key financial parameters of the Company's performance
during the year under review:
(' in million)
articulars |
Standalone |
Consolidated |
|
FY 2024 |
FY 2023 |
FY 2024 |
FY 2023 |
evenue from perations |
8,649.29 |
8,586.73 |
10,813.05 |
9,263.80 |
ther Income |
107.18 |
87.34 |
124.89 |
91.98 |
3tal Income |
8,756.47 |
8,674.07 |
10,937.94 |
9,355.78 |
otal
xpenses |
7,819.49 |
7,891.00 |
9,642.65 |
8,437.83 |
rofit before ix |
936.98 |
783.07 |
1,295.29 |
917.95 |
otal Tax xpenses |
255.37 |
207.55 |
351.84 |
238.41 |
rofit for the ear |
681.61 |
575.52 |
943.45 |
679.54 |
2. REVIEW OF OPERATIONS AND STATE OF THE COMPANY'S AFFAIRS
The Company's revenue from operations has grown at a healthy rate of ~38% CAGR over the
past 3 years and the CDMO business continues to attract considerable interest. While the
demand remains robust, the decline in API prices negatively affected business performance
as compared to FY 2023. During FY 2024, we have 190+ CDMO customers with revenue from
CDMO business contributed nearly 58%. The performance of the domestic generic business has
improved, supported by a steadily growing Pan India network of distributors, stockists and
pharmacies. The domestic branded generic business contributed approximately 18% to our
revenue in FY 2024.
During FY 2024 The Company's international branded generic business is primarily
focused on export to emerging and semi-regulated international markets with a growing
presence in regulated markets such as the UK and Canada. The Company had exported its
branded generics to 25 countries. Revenue from this segment contributed approximately 11%
in FY 2024. The Company had acquired Sharon Bio-Medicine Limited ("Sharon")
through CIRP process in June 2023. Sharon has strong CDMO formulation manufacturing
capabilities including API manufacturing and it caters majorly to international markets
including Canada, UK, Europe, Australia, Korea and Vietnam. Revenue contribution from this
business is nearly 13%.
Standalone Performance
During the year under review, on standalone basis revenue from operations was '
8,649.29 million in FY 2024 which was 0.73% higher than the revenue of ' 8,586.73
million in FY 2023. This growth was influenced by price adjustments of the products under
the cost-plus model and the prevailing API prices. The profit before tax for FY 2024 was
at ' 936.98 million with a profit for the year of ' 681.61 million. In
Comparison, FY 2023 reported a profit before tax of ' 783.07 million and a profit
for the year of ' 575.52 million.
Consolidated Performance
During the year under review, on consolidated basis revenue from operations was of '
10813.05 million in FY 2024 which was 16.72 % higher than the revenue of ' 9,263.80
million in FY 2023. The profit before tax for the FY 2024 was ' 1295.29 million
with a profit for the year was ' 943.45 million. In comparison, FY 2023 reported a
profit before tax of ' 917.95 million and profit for the year of ' 679.54
million.
3. TRANSFER TO RESERVES:
During FY 2024, the Company has not transferred any amount to Reserves. The Board of
Directors has decided to retain the entire amount of profit for FY 2024 and re-invest the
profits back into the Company to support its growth objectives.
4. DIVIDEND:
In order to conserve the resources for the future business requirements of the Company,
the Directors have decided not to recommend any dividend for the FY 2024.
5. TRANSFER OF UNCLAIMED DIVIDEND TO INVESTOR EDUCATION AND PROTECTION FUND:
The Company is not required to transfer any amount of unpaid/unclaimed dividend or any
other amount to the Investor Education and Protection Fund during the year under review.
6. SHARE CAPITAL:
As on 31 March 2024, the Authorised Share Capital of the Company is '
660,000,000.00(Rupees Six Hundred Sixty million Only) consisting of:
1. 64,000,000 (Sixty Four million) Equity Shares of ' 10.00 each and
2. 2,000,000 (Two million) Preference Shares of ' 10.00 each
Paid up share capital of the Company is ' 572,249,290.00 (Rupees Five Hundred
Seventy Two Million, Two Hundred Forty Nine Thousand and Two Hundred Ninety only) divided
into 57,224,929 equity shares of face value of ' 10.00 each. During the Financial
Year, following changes have occurred in the Capital Structure of the Company:
Particulars |
No. of shares |
Cumulative outstanding share capital (face value of '
10/- each) |
|
Equity |
Preference |
Equity |
Preference |
Share Capital at the beginning of the year, i.e. 01 April 2023 |
48,000,000 |
1,412,430 |
' 480,000,000 |
' 14,124,300.00 |
Conversion of Compulsorily Convertible Preference Shares into Equity
Shares |
1,412,430* |
(1,412,430) |
' 14,124,300.00 |
(' 14,124,300.00) |
Issuance of Equity Shares through private placement basis |
669,642** |
0 |
' 6,696,420 |
0 |
Fresh issue of Equity Shares of fully paid-up pursuant to Initial
Public Offer |
7,142,857*** |
0 |
' 71,428,570 |
0 |
Share Capital at the closing of the year i.e. 31 March, 2024 |
57,224,929 |
0 |
' 572,249,290 |
0 |
*Conversion of Compulsorily Convertible Preference Shares into Equity Shares
Cumulative Compulsorily Convertible Preference Shares ("CCCPS") which was
issued to UTI Multi Opportunities Fund I through private placement basis consisting
1,412,430 (One Million, Four Hundred Twelve Thousand and Four Hundred Thirty only)
Cumulative Compulsorily Convertible Preference Shares ("CCCPS") of face value of
' 10 each at an issue price of ' 354.00 (including premium of '
344.00) per share aggregating to ' 500,000,220.00 (Rupees Five Hundred Million and
Two Hundred Twenty only) was converted into fully paid up Equity Shares of ' 10.00
each ("Converted Equity Shares") viz. in the ratio of 1:1 vide Board resolution
dated 01 December, 2023.
**Issuance of Equity Shares through private placement basis:
The Shareholders at the Extra-Ordinary General meeting held on 01 December, 2023
approved the issuance of 669,642 (Six Hundred Sixty Nine Thousand and Six Hundred Forty
Two) equity shares of face value of ' 10.00 (Rupees Ten only) each at an issue
price of ' 448.00 (Rupees Four Hundred Forty Eight only) per share (including
premium of ' 438.00) aggregating to ' 299,999,616.00 (Rupees Two Hundred
Ninety Nine Million, Nine Hundred Ninety Nine Thousand and Six Hundred Sixteen only) in
one or more tranches, on a private placement basis to 360 ONE Special Opportunities Fund -
Series 9 and 360 ONE Special Opportunities Fund - Series 10.
***Fresh issue of Equity Shares pursuant to Initial Public Offer:
During the FY 2024, the Company had issued and allotted 7,142,857 Equity Shares of '
10.00 each, at an issue price of ' 448.00 per fully paid-up equity share (including
a premium of ' 438.00 per equity share) pursuant to Initial Public Offer as
approved by the Board of Directors in their meeting held on 27 December 2023.
The funds received pursuant to Public Issue, have been utilised for the objects stated
in the prospectus.
7. LISTING OF EQUITY SHARES OF THE COMPANY:
During the period under review, the Company got listed on stock exchange(s) through
Initial Public Offer ("IPO") for total 12,723,214 Equity Shares aggregating to '
5,700.00 million (Rupees Five Thousand and Seven Hundred million), which comprises :
a. Fresh Issue of 7,142,857 (Seven Million, One hundred Forty Two Thousand and Eight
Hundred Fifty Seven) Equity Shares of ' 10.00 each aggregating to ' 3,200.00
million (Rupees Three Thousand and Two Hundred million) and
b. Offer for Sale (OFS) of 5,580,357 (Five Million, Five Hundred Eighty Thousand and
Three Hundred Fifty Seven) Equity Shares of ' 10.00 each aggregating up to '
2500.00 million (Rupees Two Thousand and Five Hundred million).
The issue price was ' 448.00 (Rupees Four Hundred and Forty-Eight only) per
share including the premium of ' 438.00 (Rupees Four Hundred and Thirty-Eight only)
per equity share.
The above-said equity shares were allotted in the following manner: -
Sl. No |
Category of Investor |
Type of Share |
No. of shares allotted |
1 |
Anchor Investors |
Equity |
3,816,963 |
2 |
Qualified Institutional Buyers |
Equity |
2,544,643 |
|
(except Anchor Investors); |
|
|
3 |
Non-Institutional Bidders; |
Equity |
1,908,483 |
4 |
Retail Individual Bidders. |
Equity |
4,453,125 |
The Company's equity shares were listed on the Stock Exchanges viz., National Stock
Exchange of India Limited and BSE Limited w.e.f. 29 December 2023
8. DETAILS OF SUBSIDIARY, JOINT VENTURE AND ASSOCIATE COMPANIES:
As on 31 March 2024, the Company had 3 subsidiaries and there has been no material
change in the nature of business of the subsidiaries.
Pursuant to the provisions of Section 129(3) of the Act read with Rule 5 of Companies
(Accounts of Companies) Rules, 2014, a statement containing the salient features of
Financial Statements of the Company's subsidiary(s) in Form No. AOC-1 is appended as
Annexure A to the Board's Report.
The Company has formulated a Policy for Determining Material Subsidiaries. The policy
is available on the Company's website and can be accessed at
https://www.innovacaptab.com/PDF/Policy%20
determining%20material%20Subsidiaries.pdf
Further, pursuant to the provisions of Section 136 of the Act, the Standalone and
Consolidated Financial Statements of the Company along with relevant documents and
separate audited financial statements in respect of subsidiaries, are available on the
website of the Company at https://www.innovacaptab.com/ investor-relations.php
9. ACQUISITION OF SHARON BIO-MEDICINE LIMITED
The Company submitted a Resolution Plan on 22 August 2022 ("Resolution Plan")
for acquisition of Sharon Bio-Medicine Limited ("SBML'). This Resolution Plan was
approved by the Committee of Creditors of SBML on 17 November 2022 and subsequently by the
Hon'ble National Company Law Tribunal, Mumbai on 17 May 2023. A copy of the Resolution
Plan approval order is available on SBMLs website.
As a part of the Resolution Plan, the entire acquisition of Sharon Bio-Medicine
Limited("SBML') was executed through Univentis Medicare Limited, ("UML") a
Wholly Owned Subsidiary of the Company. Consequently, UML has acquired 100% stake in SBML
w.e.f. 30 June 2023. As on the date of this report, SBML is the wholly owned subsidiary of
the UML. SBML has strong CDMO formulation manufacturing capabilities including API
manufacturing and it caters majorly to international markets including Canada, UK, Europe,
Australia, Korea and Vietnam.
10. CHANGE IN THE NATURE OF BUSINESS OF THE COMPANY:
During the year under review, there was no change in the nature of business of the
Company.
11. PUBLIC DEPOSITS:
During the year under review, the Company has not accepted any deposits within the
meaning of Section 73 and 76 of the Companies Act 2013, read with Companies (Acceptance of
Deposits) Rules, 2014. As on 31 March 2024, there were no deposits lying unpaid or
unclaimed.
12. CREDIT RATING:
The Company's financial discipline and prudence is reflected in the strong credit
ratings by rating agencies. The details of credit ratings are disclosed in the Corporate
Governance Report, which forms part of the Annual Report.
13. DIRECTORS AND KEY MANAGERIAL PERSONNEL:
1. Board of Directors
The composition of the Board is in conformity with Companies Act, 2013 and Regulation
17 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015 which,
inter alia, stipulates that the Board should have an optimum combination of Executive and
Non-Executive directors. The composition of Board of Directors are as follows:
Name of the Director |
Designation |
Mr. Manoj Kumar Lohariwala |
Chairman & Whole Time Director |
Mr. Vinay Kumar Lohariwala |
Managing Director |
Mr. Jayant Vasudeo Rao |
Whole Time Director |
Mr. Archit Aggarwal |
Non-Executive - Non-Independent Director |
Mr. Sudhir Kumar Bassi |
Non-Executive - Independent Director |
Ms. Priyanka Dixit Sibal |
Non-Executive - Independent Director |
Mr. Mahendar Korthiwada |
Non-Executive - Independent Director |
Mr. Shirish Gundopant Belapure |
Non-Executive - Independent Director |
The Board of Directors of the Company is led by the Chairman and comprises of 8 (Eight)
Directors, consisting of 2 (Two) Whole-Time Directors, 1 (One) Managing Director, 4 (Four)
Non-Executive Independent Directors including 1(One) Women Director and 1 (One)
NonExecutive Non-Independent Director.
The details of the Board and committee composition, tenure of directors, areas of
expertise and other details are available in the Corporate Governance Report, which forms
part of the Annual Report.
Pursuant to the provisions of Section 149 of the Act and Regulation 25(8) of the SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing
Regulations'), the Independent Directors have submitted declarations stating that each of
them fulfils the criteria of independence as provided in Section 149(6) of the Act along
with rules framed thereunder and Regulation 16(1 )(b) of the SEBI Listing Regulations.
There has been no change in the circumstances affecting their status as Independent
Directors of the Company. In the opinion of the Board, the Independent Directors are
competent, experienced, proficient and possess the necessary expertise and integrity to
discharge their duties and functions as Independent Directors. The Independent Directors
of the Company have undertaken requisite steps towards the inclusion of their names in the
data bank of Independent Directors maintained with the Indian Institute of Corporate
Affairs.
None of the Company's directors are disqualified from being appointed as a director as
specified in Section 164 of the Act. All Directors have further confirmed that they are
not debarred from holding the office of a director under any order from SEBI or any other
such authority.
In accordance with the provisions of Section 152 of the Act and the Articles of
Association of the Company, Mr. Manoj Kumar Lohariwala (DIN:00144656), Whole Time Director
of the Company, retires by rotation at the ensuing Annual General Meeting
("AGM") and being eligible, has offered himself for re-appointment. In
compliance with Secretarial Standards-2, the brief resume, expertise, and other details of
Mr. Manoj Kumar Lohariwala is given in the notice convening the AGM. Based on the
recommendations of the Nomination and Remuneration Committee of the Company, the Board has
recommended his reappointment as Director at the ensuing AGM. During the year under
review, the Non-Executive Directors of the Company had no pecuniary relationship or
transactions with the Company, other than sitting fees, reimbursement of expenses incurred
by them for the purpose of attending meetings of the Board and its Committees or other
Company events and any other transactions as approved by the Audit Committee or the Board
which are disclosed under the Notes to Accounts. For more details about the directors,
please refer to the Corporate Governance Report.
2. Change in Key Managerial Personnel:
During the year under review there are following changes in Key Managerial Personnel:
Name of the Key Managerial Personnel |
Designation |
Nature of Change |
Effective Date |
Mr. Rishi Gupta* |
Chief Financial Officer |
Demise |
26 April 2023 |
Mr. Lokesh Bhasin |
Interim Chief Financial Officer |
Appointment |
23 May 2023 |
Mr. Mukeshkumar Siyaram Singh |
Key Managerial Personnel |
Appointment |
30 June 2023 |
Mr. Lokesh Bhasin** |
Interim Chief Financial Officer |
Cessation |
12 August 2023 |
Mr. Gaurav Srivastava |
Chief Financial Officer |
Appointment |
12 August 2023 |
Mr. Gaurav Srivastava |
Chief Financial Officer |
Cessation |
29 March 2024 |
Mr. Lokesh Bhasin |
Chief Financial Officer |
Appointment |
30 March 2024 |
*Mr. Rishi Gupta had an untimely demise on 26 April 2023.
**Mr. Lokesh Bhasin resigned as Interim Chief Financial Officer of the Company w.e.f.
11 August 2023 and has continued to be in employment of the Company as Deputy Chief
Financial Officer.
Pursuant to the provisions of Section 203 of the Act, the Key Managerial Personnel of
the Company as on the date of this report are:
Name of the Key Managerial Personnel |
Designation |
Mr. Manoj Kumar Lohariwala |
Chairman & Whole Time Director |
Mr. Vinay Kumar Lohariwala |
Managing Director |
Mr. Jayant Vasudeo Rao |
Whole Time Director |
Mr. Lokesh Bhasin |
Chief Financial Officer |
Mr. Mukeshkumar Siyaram Singh |
Key Managerial Personnel |
Ms. Neeharika Shukla |
Company Secretary & Compliance Officer |
14. POLICY ON DIRECTORS' APPOINTMENT AND REMUNERATION:
The Nomination and Remuneration policy of the company for appointment and remuneration
of Directors, Senior Management Personnel including criteria for determining
qualifications, positive attributes, independence of a Director and other matters provided
under sub-section (3) of Section 178 of the Companies Act, 2013 is available on the
Company's website at https://www.innovacaptab.
com/PDF/Nomination%20&%20Remuneration. pdf
15. PARTICULARS OF REMUNERATION:
The percentage increase in remuneration, ratio of remuneration of each Director and Key
Managerial Personnel ("KMP") (as required under the Act) to the median of
employees' remuneration, as required under Section 197 of the Act, read with rule 5(1) of
the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, are set
out in Annexure-B of this report.
16. HUMAN RESOURCES AND EMPLOYEE RELATIONS
The number of employees in the Company as on 31 March 2024 was 1,252. The Company
places
great emphasis on ensuring gender diversity within the organization. As at the
year-end, 3.91% of the employees were female. The Company is putting in efforts in this
aspect to reach an optimum gender I ratio.
1
The Company is committed to maintaining a high level
of compliance with the applicable labour laws and has implemented various policies and
process to ensure timely completion of all periodic labour compliances and for monitoring
and maintaining the status of compliances on an on-going basis.
The Company is also pleased to announce that it has implemented various initiatives for
the benefit of its employees, such as time boxing, clear agendas for each meeting, written
notes for each meeting 1 item, milestone /stage based project management,
: and leverage automation to streamline operations,
and well-being initiatives (health & fitness initiatives, employee engagement
activities, work-life balance via streamlined work timings, monthly satisfaction surveys,
employee training & skill enhancement, and rewards & recognition / belongingness).
17. ANNUAL RETURN:
Pursuant to Section 134(3)(a) and Section 92(3) of the Act read with Rule 12(1) of the
Companies (Management and administration) Rules, 2014, a copy of the Annual Return is
available on Company's website at https://www.innovacaptab.com/investor-
relations.php#fin-inf-id.
18. DIRECTORS' RESPONSIBILITY STATEMENT:
Pursuant to the provisions of Section 134(3)(c) and 134(5) of the Companies Act, 2013
the Board of Directors state and confirm that:
a. in the preparation of the annual accounts, the applicable accounting standards had
been followed along with proper explanation relating to material departures, if any;
b. they have selected such accounting policies and applied them consistently and made
judgments and estimates that are reasonable and prudent so as to give a true and fair view
of the state of affairs of the company at the end of the financial year and of the profit
of the company for that period;
c. they have taken proper and sufficient care for the maintenance of adequate
accounting records in accordance with the provisions of the Companies Act, 2013 for
safeguarding the assets of the Company and for preventing and detecting fraud and other
irregularities;
d. they have prepared the annual accounts on a going concern basis;
e. they have laid down internal financial controls to be followed by the Company and
that such internal financial controls are adequate and were operating effectively; and
f. they have devised proper systems to ensure compliance with the provisions of all
applicable laws and that such systems were adequate and operating effectively.
19. NUMBER OF MEETINGS OF THE BOARD OF DIRECTORS:
The Board meets at regular intervals to discuss and decide on Company's business policy
and strategies apart from other urgent business matter.
During the year under review, Fourteen (14) meetings of the Board of Directors were
convened. The intervening gap between two consecutive meetings was within the maximum
period mentioned under Section 173
of the Companies Act, 2013, Secretarial Standards on Board Meetings and SEBI LODR as
amended from time to time. Detailed information on the meetings of the Board is included
in the Corporate Governance Report which forms part of the Annual Report.
20. ANNUAL EVALUATION OF PERFORMANCE BY THE BOARD, ITS COMMITTES AND OF INDIVIDUAL
DIRECTORS:
Pursuant to the applicable provisions of the Act and the SEBI Listing Regulations, the
Board of Directors has put in place a process to formally evaluate the effectiveness of
the Board along with performance evaluation of each Director to be carried out on an
annual basis. The performance evaluation was carried out by the Nomination and
Remuneration Committee in its meeting held on 27 March 2024.
The evaluation was conducted via a questionnaire containing qualitative questions, with
responses provided on a rating scale. Evaluation was based on criteria such as the
composition of the Board and its Committees, their functioning, communication between the
Board, its committees and the management of the Company, and performance of the Directors
and Chairperson of the Board based on their participation in effective decision making and
their leadership abilities.
21. SEPARATE MEETING OF INDEPENDENT DIRECTORS:
As stipulated by the code of Independent Directors under Schedule IV of the Companies
Act, 2013, a separate meeting of the Independent Directors of the Company was held on 31
March 2024 to review, among other things, the performance of nonIndependent Directors and
the Board as a whole, evaluation of the performance of the Chairman and the flow of
communication between the Board and the management of the Company.
22. COMMITTEES OF THE BOARD:
During the year under review, there were no change in the composition of the Committees
of the Board. During FY 2024, the following are the Committees of the Board:
a. |
Audit Committee |
b. |
Nomination and Remuneration Committee |
c. |
Corporate Social Responsibility Committee |
d. |
Stakeholders Relationship Committee |
e. |
Risk Management Committee |
f. |
IPO Committee |
The composition of various Committees and meetings held is detailed below:
a. Audit Committee:
The Audit Committee is duly constituted in accordance with the provisions of Section
177 of the Companies Act, 2013 and Regulation 18 of the Securities and Exchange Board of
India (Listing Obligations and Disclosure Requirements) Regulations, 2015.The Audit
Committee met Ten (10) times during the FY 2024.
The Company Secretary of the Company acts as a Secretary to the Committee.
The details, including composition of the Audit Committee, terms of reference,
attendance etc., are included in the Corporate Governance Report, which is a part of this
Report.
During the year under review, the Board has accepted all recommendations of the Audit
Committee and accordingly, no disclosure is required to be made in respect of
non-acceptance of any recommendation of the Audit Committee by the Board.
b. Nomination and Remuneration Committee:
The Nomination and Remuneration Committee is duly constituted in accordance with
provisions of Section 178 of the Companies Act, 2013 and Regulation 19 of the Securities
and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations,
2015. The Nomination and Remuneration Committee met Four (4) times during the FY 2024. The
Company Secretary of the Company acts as a Secretary to the Committee.
The details, including composition of the Nomination and Remuneration Committee, terms
of reference, attendance etc., are included in the Corporate Governance Report, which is a
part of this Report.
c. Corporate Social Responsibility (CSR") Committee:
The Corporate Social Responsibility ("CSR") Committee is duly constituted in
accordance with the provision of Section 135 of the Companies Act, 2013. The Corporate
Social Responsibility Committee met Two (2) times during the FY 2024. The Company
Secretary of the Company acts as a Secretary to the Committee.
The details, including composition of the Corporate Social Responsibility Committee,
terms of reference, attendance etc., are included in the Corporate Governance Report,
which is a part of this Report.
d. Stakeholders' Relationship Committee
The Stakeholders Relationship Committee was duly constituted as per the provisions of
Section 178 of the Companies Act, 2013 and Regulation 20 of the Securities and Exchange
Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The
Stakeholders Relationship Committee met One (1) time during the FY 2024. The Company
Secretary of the Company acts as a Secretary to the Committee.
The details, including composition of the Stakeholders Relationship Committee, terms of
reference, attendance etc., are included in the Corporate Governance Report, which is a
part of this Report.
e. Risk Management Committee:
The Risk Management Committee was duly constituted pursuant the provisions of the
Companies Act, 2013 and Regulation 21 Securities and Exchange Board of India (Listing
Obligations and Disclosure Requirements) Regulations, 2015. The Risk Management Committee,
met Two (2) times during the FY 2024 The Company Secretary of the Company acts as a
Secretary to the Committee.
The Company has a well-defined risk management policy and framework which sets out the
objectives and elements of risk management within the Company and helps to promote risk
awareness across the organisation and integrate risk management within the corporate
culture. The Risk Management Policy inter-alia includes well defined risk management roles
within the Company, risk appetite and risk tolerance capacity of the Company,
identification and assessment of the likelihood and impact of risk, risk handling and
response strategy and reporting of existing and new risks associated with the Company's
activities in a structured manner. This facilitates timely and effective management of
risks and opportunities and achievement of the Company's objectives.
The Board, the Audit Committee and the Risk Management Committee have the
responsibility for overseeing all risks. The Risk Management Committee is, inter-alia,
authorised to monitor
and review the risk assessment, mitigation and risk management plans for the Company
from time to time and report the existence, adequacy, and effectiveness of the above
process to the Board on a periodic basis.
The details of composition of the Risk Management Committee, their terms of reference,
meetings held and attendance of the Committee Members thereat during the financial year
under review are provided in the section titled Report on Corporate Governance, which
forms part of the Annual Report.
f. IPO Committee:
The IPO Committee was duly constituted by the Board of Directors of the Company on 09
May 2022, for the purpose of giving effect to the proposed initial public offering of the
equity shares of the Company. The IPO Committee met Six (6) times during the FY 2024.The
Company Secretary of the Company acts as a Secretary to the Committee.
The details, including composition of the IPO Committee, attendance are included in the
Corporate Governance Report, which is a part of this Report. The IPO committee was
dissolved by Board of Directors in their meeting held on 18 January 2024
23. AUDITORS:
Statutory Auditors and Statutory Auditor's Report: M/s. B S R & Co. LLP, Chartered
Accountants Firm Registration Number: 101248W/W-100022, were
reappointed as Statutory Auditors of the Company, for a term of five consecutive years
to hold office from the conclusion of 17thAnnual General Meeting of the Company
held on 30 November 2021 till the conclusion of 22nd AGM to be held in the
Financial Year 2026 at such remuneration plus out of pocket expenses and applicable taxes,
as may be mutually agreed between the Company and the Auditor.
Pursuant to Section 139 and 141 of the Act and relevant Rules prescribed thereunder,
the Statutory Auditors have confirmed that they are not disqualified from continuing as
Auditors of the Company. There were no qualifications, reservations, adverse remarks or
disclaimers made by the Statutory Auditor in their Report. The Notes to the Financial
Statements referred in the Auditors Report are self-explanatory and therefore do not call
for any comments under Section 134 of the Companies Act, 2013. The Auditor's Report is
enclosed with the Financial Statements in the Annual Report.
Cost Auditors:
Pursuant to the provisions of Section 148 of the Companies Act, 2013 read with the
Companies (Cost Records and Audit) Rules, 2014, as amended from time to time, the Company
is required to maintain Cost Records and have them audited every year. Accordingly, the
Company has made and maintained the cost accounts and records, as required.
Based on recommendation of the Audit Committee and approved by the Board, M/s Gurvinder
Chopra & Co., Cost Accountant, Firm Registration Number: 100260 appointed as the Cost
Auditors of the Company to carry out audit of the cost records of the Company for the FY
2024.
The resolution seeking ratification of the remuneration to the said cost auditors for
the FY 2025 is set out in the Notice calling the 20th Annual General Meeting of
the Company. The Cost Auditors have certified that their appointment is within the limits
of Section 141(3) (g) of the Companies Act, 2013 and that they are not disqualified from
appointment within the meaning of the said Act.
Secretarial Auditors and Secretarial Audit Report:
Pursuant to the provisions of Section 204 of the Companies Act, 2013, read with
Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, M/s Jaspreet
Dhawan & Associates, Company Secretaries (FCS No. 9372, C.P. No. 8545, Peer Review
S2009PB119300), were appointed as the Secretarial Auditors of the Company to undertake the
Secretarial Audit of the Company for FY 2024. The Secretarial Audit Report in the
prescribed Form No. MR-3 received from M/s Jaspreet Dhawan & Associates, Company
Secretaries (FCS No. 9372) for the year ended 31 March 2024, is annexed as "Annexure
C" and forms part of this report.
There are no qualifications or observations or adverse remarks or disclaimer of the
Secretarial Auditors in its Report.
Pursuant to master circular No. SEBI/HO/CFD/PoD2/ CIR/P/2023/120 dated July 11, 2023,
issued by Securities and Exchange Board of India, the Company has obtained Annual
Secretarial Compliance Report for the FY 2024, from M/s Jaspreet Dhawan & Associates,
Company Secretaries on compliance of all applicable SEBI Regulations and circulars /
guidelines issued thereunder and the copy of the same has been submitted to the Stock
Exchanges on 27 May 2024.
Internal Auditors:
Pursuant to the provisions of Section 138 of the Companies Act, 2013, read with
Companies (Accounts)
Rules, 2014, M/s Goel Anish & Associates, Chartered Accountants (Firm's
Registration No. 036505N) were appointed as the Internal Auditors of the Company to
conduct the Internal Audit for the FY 2024.
24. MAINTENENCE OF THE COST RECORDS:
For the FY 2024, the provisions of Cost Audit as specified by the Central Government
under Section 148 of the Act read with the Rules framed thereunder, were applicable to the
Company. As per Section 148 of the Act read with the Companies (Cost Records and Audit)
Rules, 2014, the Company was required to maintain cost records for FY 2024 and
accordingly, such accounts and records are maintained.
25. DETAILS IN RESPECT OF FRAUD REPORTED BY AUDITORS:
Pursuant to Section 143(12) of the Companies Act, 2013, during the year under review
there were no frauds reported by the Statutory Auditors and Secretarial Auditors of the
Company to the Audit Committee or the Board of Director Hence, there is nothing to report
under Section 134(3) (ca) of the Companies Act, 2013.
26. MANAGEMENT DISCUSSION AND ANALYSIS:
The Management Discussion and Analysis for the year under review, as stipulated under
the SEBI (Listing Obligations and Disclosure Requirements) Regulations, is available as
separate section of this annual report.
27. BUSINESS RESPONSIBILITY AND SUSTAINABILITY REPORT :
The Securities and Exchange Board of India ("SEBI"), in May, 2021, introduced
new sustainability related reporting requirements to be reported in the specific format of
Business Responsibility and Sustainability Report ("BRSR"). BRSR is a notable
departure from the existing Business Responsibility Report ("BRR") and a
significant step towards giving platform to the companies to report the initiatives taken
by them in areas of environment, social and governance. Further, SEBI has mandated top
1,000 listed companies, based on market capitalization, to transition to BRSR from FY2023
onwards. BRSR report is available as separate section of this annual report.
28. INTERNAL FINANCIAL CONTROL SYSTEMS AND THEIR ADEQUACY:
The Board has adopted the policies and procedures for ensuring the orderly and
efficient conduct of its business, including adherence to Company Policies,
safeguarding of assets, prevention and detection of frauds and errors, the accuracy and
completeness of the accounting records and timely preparation of reliable financial
disclosures.
The Audit Committee evaluates the efficiency and adequacy of Financial Control system
in the Company, its compliance with operating systems, accounting procedures at all
locations of the Company and strives to maintain a high Standard of Internal Financial
Control.
During the year under review, no material or serious observation has been received from
the Auditors of the Company citing inefficiency or inadequacy of such controls. An
extensive internal audit was carried out by M/s. Goel Anish & Associates, Chartered
Accountants and post audit reviews were also carried out to ensure follow up on the
observations made.
29. VIGIL MECHANISM POLICY:
The Company has adopted a Whistleblower Policy and has established a vigil mechanism
for directors and employees in confirmation with Section 177 of the Act and the Rules
framed thereunder and Regulation 22 of the Listing Regulations to report their concerns.
For more details on the Whistleblower Policy please refer to the Corporate Governance
Report and the Business Responsibility and Sustainability Report ("BRSR").
The Company is committed to adhere to the highest standards of ethical, moral and legal
conduct of business operations and in order to maintain these standards the Company
encourages the employees to raise their genuine concerns without fear of criticism.
Therefore, Company has Vigil Mechanism and Whistle Blower Policy and has established
necessary framework to protect genuine whistle blowers, employees, third parties from any
unfair treatment.
The Vigil Mechanism and Whistle Blower Policy is available on the website of the
Company at https://www.innovacaptab.com/PDF/Vigil%20%20
Mechanism%20&%20Whistle%20Blower%20Policy. pdf
30. CORPORATE SOCIAL RESPONSIBILITY INITIATIVE:
We believe that while the growth and success of our business is our priority, we can
reach our greater goals only if we cater to the needs of the communities where we operate.
Community development involves implementing a long-term plan to establish a supportive and
lasting framework for the progress of communities. As a result, the Company's approach to
Corporate Social Responsibility ("CSR") extends
beyond fulfilling legal obligations and instead focuses on generating social and
environmental benefits.
The CSR committee of the Board oversees and guides our CSR approach and deployment in
line with the CSR Policy adopted by the Board. The CSR Policy covers the focus/thrust
areas around which the CSR programmes, projects and activities are planned for creating a
significant positive impact on targeted stakeholder groups. During the financial year
under review, the CSR efforts of the Company continued to be directed towards its focus
areas in line with the Company's CSR Policy positively.
A brief outline of the Policy on CSR is available on the website of the Company at
https://www.innovacaptab. com/PDF/Corporate%20Social%20Responsbility%20 Policy.pdf
The Annual Report on CSR activities is enclosed as "Annexure D".
31. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND
OUTGO:
The Company consciously makes all efforts to conserve energy across its operations. The
information pertaining to conservation of energy, technology absorption, Foreign Exchange
Earnings and Outgo as required under Section 134 (3)(m) of the Act, read with Rule 8(3) of
the Companies (Accounts) Rules, 2014 is furnished in "Annexure E" and forms part
of this Report.
32. PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS:
In accordance with the provisions of Section 186 of the Act, the details of Loans,
Guarantees and Investments made by the Company as of 31 March 2024 are provided in the
notes to the accounts of the Standalone Financial Statements which forms part of the
Annual Report.
33. DIRECTORS & OFFICERS LIABILITY INSURANCE:
The Company has in place the Directors & Officers Liability Insurance for all its
Directors (including Independent Directors) and Officers of the Company in line with
Regulation 25(10) of the SEBI Listing Regulations.
34. PARTICULARS OF CONTRACTS OR ARRANGEMENTS WITH RELATED PARTIES:
The Company has formulated a Policy on materiality of dealing with related party
transactions and the
same has been hosted on its website at https://www.
innovacaptab.com/investor-relations.php#fin-inf-id All applicable related party
related party transactions are placed before the Audit Committee for their review and
approval. Further, prior to entering into related party transactions of repetitive nature
and in the ordinary course of business at an arms' length basis, omnibus approval of the
Audit Committee is obtained. Further, the Company has not entered into any material
related party transaction during the year except with wholly owned subsidiary.
All the transactions entered during the financial year under review with the related
parties referred to in Section 188 of the Act were in the ordinary course of the business
and on the arm's length basis and are reported /stated in the Notes to the Accounts of the
Standalone Financial Statements of the Company which forms part of the Annual Report.
Accordingly, the disclosure of related party transactions as required under Section
134(3)(h) of the Act, in Form AOC-2 is not applicable to the Company, since there were no
material transactions with related parties.
35. MATERIAL CHANGES AND COMMITMENT, IF ANY, AFFECTING THE FINANCIAL POSITION OF THE
COMPANY THAT OCCURRED BETWEEN THE END OF THE FINANCIAL YEARTO WHICH THE FINANCIAL
STATEMENTS RELATE AND THE DATE OF THE REPORT:
No material changes or commitments affecting the financial position of the Company
occurred between the end of the Financial Year to which these financial statements relate
and the date of this report, except as disclosed in this Report.
36. THE DETAILS OF DIFFERENCE BETWEEN AMOUNT OF THE VALUATION DONE AT THE TIME OF
ONETIME SETTLEMENT AND THE VALUATION DONE WHILE TAKING LOAN FROM THE BANKS OR FINANCIAL
INSTITUTIONS ALONG WITH THE REASONS THEREOF: The Company was not required to obtain this
valuation report.
37. DETAILS OF SIGNIFICANT MATERIAL ORDERS PASSED BY THE REGULATORS / COURTS / TRIBUNAL
IMPACTING THE GOING CONCERN STATUS AND COMPANY'S OPERATION IN FUTURE:
There are no significant material orders passed by the Regulators / Courts / Tribunal
which would impact the going concern status of the Company or will have bearing on
company's operations.
38. RISK AND AREAS OF CONCERN:
The Company has laid down a well-defined Risk Management Policy and Business Continuity
Plan to
Identify the Risk
Assessment of Risk
Measurement and Control
Continuous Assessment
Risk mitigation process
a detailed exercise is carried out by the Business Continuity Management
("BCM") designated by Board to identify, evaluate, manage and monitor both
business and non-business risk. In this regard, the Company continues to exercise prudence
on its Strategic Risks, Regulatory Risks, Legal and Secretarial Compliance risks,
Financials Risks, Operational Risks, People Risks along with some other risk which might
affect business operation. The Board periodically reviews the risks and suggests steps to
be taken to control and mitigate the same through a properly defined framework. A copy of
the risk management policy is placed on the Company's website www.innovacaptab.com
and can be accessed at https://www.innovacaptab.com/PDF/
Risk%20Management%20Policy.pdf.
The following are the key risks faced by the Company and mitigation plans for each of
those risks:
Risk Mitigation Plan |
|
Competition & Supplier Risk |
Our Company is focused on building economies of scale, into the
business. Company has strengthened our business' long-term relation with customer Our
Company has developed alternative suppliers to safeguard the raw material supply chain. |
Regulatory & Secretarial Compliance Risks |
Our Company has framework in place to timely Comply with the Regulatory
& Secretarial Compliances. |
Legal Risks |
Our legal and compliance team is dedicated to ensuring strict adherence
to all relevant regulations. In close collaboration with the Board of Directors and senior
management, they work tirelessly to uphold these regulatory standards. Additionally, the
company is in the process of implementing advanced compliance management software, further
strengthening our commitment to regulatory excellence. |
Financials Risks |
Our Company has robust strategy and framework in place to timely
Compliances of all applicable Acts Statutes and Internal Control over Financial Reporting. |
Risk Mitigation Plan
Operational Company's facilities are all as per GMP Risks standards. We also house a
R&D team
which does rigorous checks to ensure the quality and efficacy of the products as per
customer standards.
As the equity shares of the Company got listed on National Stock Exchange of India
Limited and BSE Limited on 29 December 2023 and is forming part of the top 1000 listed
entities determined on the basis of market capitalisation, as at the end of the immediate
previous financial year i.e. 31 March 2024, Regulation 21 of the SEBI LODR with respect to
Risk Management Committee has become applicable to the Company. Accordingly, the Board of
Directors have constituted Risk Management Committee for monitoring and reviewing of the
risk assessment, mitigation and risk management plan from time to time.
39. COMPLIANCE WITH SECRETARIAL STANDARDS:
The Company has devised proper systems to ensure compliance with the applicable
Secretarial Standards issued by the Institute of Company Secretaries of India and has
complied with all the applicable provisions of the during the year under review.
40. PREVENTION OF INSIDER TRADING:
For dealing in shares and Unpublished Price Sensitive Information ("UPSI") of
the Company and in compliance with the Securities and Exchange Board of India (Prohibition
of Insider Trading) Regulations, 2015 ("SEBI Insider Trading Regulations") the
Company has formulated and adopted the following:
Code of internal procedures and conduct for regulating, monitoring and reporting
of trading by insiders
Code of practices and procedures for fair disclosure of UPSI
The aforesaid policies and codes are designed to maintain the highest ethical standards
of trading in securities of the Company, to regulate, monitor and ensure pre- clearance
and reporting of trades by the Designated Persons (including their immediate relatives)
identified basis their functional role/seniority in the Company/ its wholly owned
subsidiary Company (including step down subsidiary), advise designated persons and
employees on protection of UPSI and on the compliances and procedures to be followed while
dealing with securities and UPSI of the Company including entry in Structured Digital
Database, investigation procedure in case of leak/suspected leak of UPSI and cautions them
of the consequences of violations. The
said Code is available on the website of the Company at
https://www.innovacaptab.com/PDF/Code%20of%20
internal%20procedures%20and%20conduct%20for%20
regulating.%20monitoring%20and%20reporting%20 of%20trading%20by%20insiders.pdf
41. INFORMATION UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION,
PROHIBITION AND REDRESSAL) ACT, 2013:
The Company has zero tolerance for sexual harassment at workplace and has adopted a
Policy on Prevention, Prohibition and Redressal of Sexual Harassment ("POSH"
policy) at Workplace in line with the provisions of the Sexual Harassment of Women at
Workplace (Prevention, Prohibition and Redressal) Act, 2013 and the Rules there under to
provide a safe and harassment free workplace for every individual working in any office of
the Company.
The Company has duly set up an Internal Complaints Committee ("ICC") in line
with the requirements of The Sexual Harassment of Women at the Workplace (Prevention,
Prohibition & Redressal) Act, 2013, to redress complaints received regarding sexual
harassment.
The Company did not receive any complaint of sexual harassment during the year under
review.
42. OTHER INFORMATION:
a. Green Initiative:
To support the "Green Initiative" undertaken by the
Ministry of Corporate Affairs (MCA), to contribute
towards a greener environment, the Company has already initiated/ implemented the same.
As permitted, delivery of notices, documents, annual reports etc. are being sent to
members via electronic mode.
b. General:
No disclosure or reporting is required in respect of the following items as there were
no transactions on these items during the year under review:
1) Issue of equity shares with differential rights as to dividend, voting or otherwise.
2) Issue of shares (including sweat equity shares) to employees of the Company under
any scheme.
3) Buy back of the shares of the Company
4) There is no proceeding pending under the Insolvency and Bankruptcy Code, 2016.
5) There was no instance of onetime settlement with any Bank or Financial Institution.
43. ACKNOWLEDGEMENT:
The Directors also acknowledges and appreciates the contribution made by dedicated and
loyal and all past and present employees at all levels of the Company for their hard work,
dedication, commitment and efforts. The Directors also wish to place on record their
appreciation for the continuous co-operation, assistance and support extended by all
stakeholders, Government Authorities, Financial Institutions, Banks, Customers, Dealers,
Suppliers etc. of the Company.
|
For and on behalf of the Board of Directors |
|
Innova Captab Limited |
|
Manoj Kumar Lohariwala |
Date: 09 August 2024 |
Chairman and Whole-Time Director |
Place: Panchkula |
DIN: 00144656 |